Computer-aided drug design of bioactive natural products

Current Topics in Medicinal Chemistry

Volumn 15, Issue 18, 2015, Pages 1780-1800

  Prachayasittikul, Veda ^a   Worachartcheewan, Apilak ^a   Shoombuatong, Watshara ^a   Songtawee, Napat ^a   Simeon, Saw ^a   Prachayasittikul, Virapong ^a   Nantasenamat, Chanin ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Biological activity; Computer aided drug design; Data mining; Drug discovery; Natural products

Indexed keywords

CARFILZOMIB; CURCUMIN; HOMOHARRINGTONINE; MITOXANTRONE; NATURAL PRODUCT; NEW DRUG; BIOLOGICAL PRODUCT;

ALGORITHM; ARTICLE; AUTOMATION; COMPUTER AIDED DESIGN; COMPUTER PREDICTION; COMPUTER SIMULATION; DRUG ABSORPTION; DRUG ACTIVITY; DRUG DATABASE; DRUG DESIGN; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SCREENING; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; INTERNET; MATHEMATICAL MODEL; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; PHARMACOPHORE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; QUANTITATIVE STRUCTURE PROPERTY RELATION; TRADITIONAL MEDICINE; CHEMICAL STRUCTURE; CHEMISTRY; SYNTHESIS;

BIOLOGICAL PRODUCTS; COMPUTER-AIDED DESIGN; DRUG DESIGN; MODELS, MOLECULAR; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84934753904     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026615666150506151101     Document Type: Article

References (235)

1. Solecki, R.S. Shanidar IV, a Neanderthal flower burial in northern Iraq. Science, 1975, 190(4217), 880-881.
2. Cragg, G.M.; Newman, D.J. Biodiversity: A continuing source of novel drug leads. Pure Appl. Chem., 2005, 77(1), 7-24.
3. Hartwell, J.L. Plants used against cancer. A Survey. Lloydia, 1967, 30, 379-436.
4. Cragg, G.M.; Newman, D.J. Natural products: A continuing source of novel drug leads. Biochim. Biophys. Acta., 2013, 1830(6), 3670-3695.
5. Butler, M.S. The role of natural product chemistry in drug discov- ery. J. Nat. Prod., 2004, 67(12), 2141-2153.
6. Kinghorn, A.D.; Pan, L.; Fletcher, J.N.; Chai, H. The relevance of higher plants in lead compound discovery programs. J. Nat. Prod., 2011, 74(6), 1539-1555.
7. Hicks, S. Desert plants and people, 2nd ed.; The Naylor Company Book Publisher of the Southwest: Texas, 1971.
8. Stocker-Worgotter, E. Metabolic diversity of lichen-forming asco- mycetous fungi: culturing, polyketide and shikimatemetabolite production, and PKS genes. Nat. Prod. Rep., 2008, 25(1), 188-200.
9. Dias, D.A.; Urban, S.; Roessner, U. A historical overview of natu- ral products in drug discovery. Metabolites, 2012, 2(2), 303-336.
10. Jensen, A. Present and future needs for algae and algal products. In: Fourteenth International Seaweed Symposium; Chapman, A.R.O.; Brown, M.T.; Lahaye, M., Ed.; Springer: Netherlands, 1993, Vol. 85, pp.15-23.
11. Smith, E. Medicinal plants in folk tradition: An ethnobotany of Britain and Ireland. HortScience, 2005, 40(3), 505-505.
12. Borlase, W.; Pool, P.; Turk, F. The natural history of Cornwall; E. & W. Books, 1970.
13. Furuya, T.; Ikuta, A.; Syōno, K. Alkaloids from callus tissue of Papaver somniferum. Phytochemistry, 1972, 11(10), 3041-3044.
14. Sneader, W.E., Drug Discovery (The History). In: Van Nostrand's Scientific Encyclopedia; John Wiley & Sons, Inc., 2005.
15. Leonti, M. Traditional medicines and globalization: current and future perspectives in ethnopharmacology. Front. Pharmacol., 2013, 4(92), 1-13.
16. Touwaide, A.; Appetiti, E. Knowledge of Eastern materia medica (Indian and Chinese) in pre-modern Mediterranean medical traditions: A study in comparative historical ethnopharmacology. J. Ethnopharmacol., 2013, 148(2), 361-378.
17. Sharma, H.M. Contemporary Ayurveda. In: Fundamentals of Complementary and Alternative Medicine; Micozzi, M.S., Ed.; Saun-ders Elsevier: St. Louis, Missouri, 2011, pp. 495–508.
18. Samhita, S.; Sharma, P. Chaukhamba Orientalia; Varanasi: India, 1997.
19. Patwardhan, B.; Warude, D.; Pushpangadan, P.; Bhatt, N. Ayurve-da and traditional Chinese medicine: A comparative overview. Evid. Based Complement. Alternat. Med., 2005, 2(4).
20. Lu, A.; Jiang, M.; Zhang, C.; Chan, K. An integrative approach of linking traditional Chinese medicine pattern classification and bio-medicine diagnosis. J. Ethnopharmacol., 2012, 141(2), 549-556.
21. Park, J.; Park, H.J.; Lee, H.J.; Ernst, E. What's in a name? A systematic review of the nomenclature of Chinese medical formulae. Am. J. Chin. Med., 2002, 30(02n03), 419-427.
22. Yin, C.S.; Ko, S.G. Introduction to the history and current status of evidence-based Korean medicine: A unique integrated system of allopathic and holistic medicine. Evid. Based Complement. Alternat. Med., 2014, 2014, 6.
23. Saralamp, P.; Chuakul, W.; Temsiririrkkul, R.; Clayton, T. Medicinal plants in Thailand. Vol. 1, 1996.
24. Yu, F.; Takahashi, T.; Moriya, J.; Kawaura, K.; Yamakawa, J.; Kusaka, K.; Itoh, T.; Morimoto, S.; Yamaguchi, N.; Kanda, T. Traditional Chinese medicine and Kampo: A review from the distant past for the future. J. Int. Med. Res., 2006, 34(3), 231-239.
25. Sumantran, V.N.; Tillu, G. Insights on personalized medicine from Ayurveda. J. Altern. Complement. Med., 2012, 19(4), 370-375.
26. Shim, E.B.; Lee, S.; Kim, J.Y.; Earm, Y.E. Physiome and Sasang constitutional medicine. J. Physiol. Sci., 2008, 58(7), 433-440.
27. Joshi, K.; Ghodke, Y.; Shintre, P. Traditional medicine and ge-nomics. J. Ayurveda Integr. Med., 2010, 1(1), 26.
28. Prasher, B.; Negi, S.; Aggarwal, S.; Mandal, A.; Sethi, T.; Deshmukh, S.; Purohit, S.; Sengupta, S.; Khanna, S.; Mohammad, F.; Garg, G.; Brahmachari, S.; Consortium, I.G.V; Mukerji, M. Whole genome expression and biochemical correlates of extreme constitutional types defined in Ayurveda. J. Transl. Med., 2008, 6(1), 48.
29. Ghodke, Y.; Joshi, K.; Patwardhan, B. Traditional medicine to modern pharmacogenomics: Ayurveda Prakriti type and CYP2C19 gene polymorphism associated with the metabolic variability. Evid. Based Complement. Alternat. Med., 2011, 2011.
30. Chen, S.; Lv, F.; Gao, J.; Lin, J.; Liu, Z.; Fu, Y.; Liu, Y.; Lin, B.; Xie, Y.; Ren, X.; Xu, Y.; Fan, X.; Xu, A. HLA class II polymorphisms associated with the physiologic characteristics defined by traditional Chinese medicine: linking modern genetics with an ancient medicine. J. Altern. Complement. Med., 2007, 13(2), 231-240.
31. Chao, M.; Zou, D.; Zhang, Y.; Chen, Y.; Wang, M.; Wu, H.; Ning, G.; Wang, W. Improving insulin resistance with traditional Chinese medicine in type 2 diabetic patients. Endocrine, 2009, 36(2), 268-274.
32. Efferth, T.; Miyachi, H.; Bartsch, H.. Pharmacogenomics of a traditional Japanese herbal medicine (Kampo) for cancer therapy. Cancer Genomics Proteomics, 2007, 4(2), 81-91.
33. Matsumoto, C.; Kojima, T.; Ogawa, K.; Kamegai, S.; Oyama, T.; Shibagaki, Y.; Kawasaki, T.; Fujinaga, H.; Takahashi, K.; Hikiami, H.; Goto, H.; Kiga, C.; Koizumi, K.; Sakurai, H.; Muramoto, H.; Shimada, Y.; Yamamoto, M.; Terasawa, K.; Takeda, S.; Saiki, I. A proteomic approach for the diagnosis of 'oketsu' (blood stasis), a pathophysiologic concept of Japanese traditional (Kampo) medicine. Evid. Based Complement. Alternat. Med., 2008, 5(4), 463-74.
34. Won, H.H.; Lee, S.; Jang, E.; Kim, K.K.; Park, Y.K.; Kim, Y.J.; Kim, Y.S.; Kim, B.Y.; Kim, J.Y.; Kim, J.W. A genome-wide scan for the Sasang constitution in a Korean family suggests significant linkage at chromosomes 8q11.22–23 and 11q22.1–3. J. Altern. Complement. Med., 2009, 15(7), 765-769.
35. Kim, H.J.; Hwang, S.Y.; Kim, J.H.; Park, H.J.; Lee, S.G.; Lee, S.W.; Joo, J.C.; Kim, Y.K. Association between genetic polymorphism of multidrug resistance 1 gene and Sasang constitutions. Evid. Based Complement. Alternat. Med., 2009, 6 Suppl 1, 73-80.
36. Lee, T.G.; Koh, B.; Lee, S. Sasang constitution as a risk factor for diabetes mellitus: a cross-sectional study. Evid. Based Complement. Alternat. Med., 2009, 6 Suppl 1, 99-103.
37. Rates, S.M.K. Plants as source of drugs. Toxicon, 2001, 39(5), 603-613.
38. Tilburt, J.C.; Kaptchuk, T.J. Herbal medicine research and global health: an ethical analysis. Bull. World Health Organ., 2008, 86(8), 594-599.
39. Benzie, I.F.; Wachtel-Galor, S. Herbal medicine: biomolecular and clinical aspects; CRC Press, 2011.
40. Taylor, J.L.S.; Rabe, T.; McGaw, L.J.; Jäger, A.K.; Staden, J.V. Towards the scientific validation of traditional medicinal plants. Plant Growth Regul., 2001, 34(1), 23-37.
41. DerMarderosian, A.; Beutler, J.A. The review of natural products: the most complete source of natural product information.; Facts and Comparisons, 2002.
42. Jiratchariyakul, W.; Mahady, G.B. Overview of botanical status in EU, USA, and Thailand. Evid. Based Complement. Alternat. Med., 2013, 2013, 13.
43. Hughes, J.P.; Rees, S.; Kalindjian, S.B.; Philpott, K.L. Principles of early drug discovery. Br. J. Pharmacol., 2011, 162(6), 1239-49;
44. van de Waterbeemd, H.; Gifford, E. ADMET in silico modelling: Towards prediction paradise? Nat. Rev. Drug Discov., 2003, 2(3), 192-204.
45. Mandal, S.; Moudgil, M.; Mandal, S.K. Rational drug design. Eur. J. Pharmacol., 2009, 625(1-3), 90-100.
46. Fox, S.; Farr-Jones, S.; Sopchak, L.; Boggs, A.; Nicely, H.W.; Khoury, R.; Biros, M. High-throughput screening: update on practices and success. J. Biomol. Screen, 2006, 11(7), 864-9.
47. Reymond, J.L.; Ruddigkeit, L.; Blum, L.; van Deursen, R. The enumeration of chemical space. Wiley Interdiscip. Rev. Comput. Mol. Sci., 2012, 2(5), 717-733.
48. Wikberg, J.E.S.; Eklund, M.; Willighagen, E.L.; Spijuth, O.; La-pins, M.; Engkvist, O.; Alvarsson, J. Drug discovery and development, In: Introduction of Pharmaceutical Bioinformatics; Oakleaf Academic Publishing House: Stockholm, 2011, pp. 27-39.
49. Klopmand, G. Concepts and applications of molecular similarity, by Mark A. Johnson and Gerald M. Maggiora, eds., John Wiley & Sons, New York, 1990, 393 pp. Price: $65.00. J. Comput. Chem., 1992, 13(4), 539-540.
50. Evans, B.E.; Rittle, K.E.; Bock, M.G.; DiPardo, R.M.; Freidinger, R.M.; Whitter, W.L.; Lundell, G.F.; Veber, D.F.; Anderson, P.S.; Chang, R.S.L.; Lotti, V.J.; Cerino, D.J.; Chen T.B.; Kling, P.J.; Kunkel, K.A.; Springer, J.P.; Hirshfield, J. Methods for drug discovery: Development of potent, selective, orally effective cholecys-tokinin antagonists. J. Med. Chem., 1988, 31(12), 2235-2246.
51. Duarte, C.D.; Barreiro, E.J.; Fraga, C.A.M. Privileged structures: A useful concept for the rational design of new lead drug candidates. Mini Rev. Med. Chem., 2007, 7(11), 1108-1119.
52. Liu, Z.; Chen, X.; Yu, L.; Zhen, X.; Zhang, A. Synthesis and pharmacological investigation of novel 2-aminothiazole-privileged aporphines. Bioorg. Med. Chem., 2008, 16(14), 6675-6681.
53. Ventosa-Andrés, P.; Hradilová, L.; Krchňák, V. Privileged structures as peptide backbone constraints: Polymer-supported stereose-lective synthesis of benzimidazolinopiperazinone peptides. ACS Comb. Sci., 2014, 16(7), 359-366.
54. Yu, B.; Yu, D.Q.; Liu, H.M. Spirooxindoles: Promising scaffolds for anticancer agents. Eur. J. Med. Chem., In Press.
55. Welsch, M.E.; Snyder, S.A.; Stockwell, B.R. Privileged scaffolds for library design and drug discovery. Curr. Opin. Chem. Biol., 2010, 14(3), 347-361.
56. Lipinski, C.A.; Lombardo, F.; Dominy, B.W.; Feeney, P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev., 1997, 23(1-3), 3-25.
57. van de Waterbeemd, H.; Smith, D.A.; Beaumont, K.; Walker, D.K. Property-based design: Optimization of drug absorption and phar-macokinetics. J. Med. Chem., 2001, 44(9), 1313-1333.
58. Leeson, P.D.; Springthorpe, B. The influence of drug-like concepts on decision-making in medicinal chemistry. Nat. Rev. Drug Dis-cov., 2007, 6(11), 881-890.
59. Kola, I.; Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov., 2004, 3(8), 711-715.
60. Merlot, C. Computational toxicology-a tool for early safety evaluation. Drug Discov. Today, 2010, 15(1-2), 16-22.
61. Li, A.P. Screening for human ADME/Tox drug properties in drug discovery. Drug Discov. Today, 2001, 6(7), 357-366.
62. Grover, J.; Kumar, V.; Singh, V.; Bairwa, K.; Sobhia, M.E.; Jachak, S.M. Synthesis, biological evaluation, molecular docking and theoretical evaluation of ADMET properties of nepodin and chrysophanol derivatives as potential cyclooxygenase (COX-1, COX-2) inhibitors. Eur. J. Med. Chem., 2014, 80, 47-56.
63. Gupta, N.; Sitwala, N.; Patel, K. Pharmacophore modelling, validation, 3D virtual screening, docking, design and in silico ADMET simulation study of histone deacetylase class-1 inhibitors. Med. Chem. Res., 2014.
64. Kartasasmita, R.E.; Musfiroh, I.; Muhtadi, A.; Ibrahim, S. Binding affinity of asiatic acid derivatives design against inducible nitric oxide synthase and ADMET prediction. J. App. Pharm. Sci., 2014, 4(2), 75-80.
65. Li, D.; Chen, L.; Li, Y.; Tian, S.; Sun, H.; Hou, T. ADMET evaluation in drug discovery. 13. Development of in silico prediction models for p-glycoprotein substrates. Mol. Pharm., 2014, 11(3), 716-726.
66. Rashid, U.; Hassan, S.F.; Nazir, S.; Wadood, A.; Waseem, M.; Ansari, F.L. Synthesis, docking studies, and in silico ADMET predictions of some new derivatives of pyrimidine as potential KSP inhibitors. Med. Chem. Res., 2014.
67. Vardhini, S.R.D. In silico evaluation for the potential naturally available drugs for breast cancer. J. Recept. Signal Transduct. Res., 2014, 34(3), 174-179.
68. Tetko, I.V. Computing chemistry on the web. Drug Discov. Today, 2005, 10(22), 1497-1500.
69. Irwin, J.J.; Shoichet, B.K. ZINC - A free database of commercially available compounds for virtual screening. J. Chem. Inf. Model., 2004, 45(1), 177-182.
70. Gaulton, A.; Bellis, L.J.; Bento, A.P.; Chambers, J.; Davies, M.; Hersey, A.; Light, Y.; McGlinchey, S.; Michalovich, D.; Al-Lazikani, B.; Overington, J.P. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res., 2012, 40(D1), D1100-D1107.
71. Wang, Y.; Xiao, J.; Suzek, T.O.; Zhang, J.; Wang, J.; Bryant, S.H. Pub Chem: a public information system for analyzing bioactivities of small molecules. Nucleic Acids Res., 2009, 37(suppl 2), W623-W633.
72. Aguero, F.; Al-Lazikani, B.; Aslett, M.; Berriman, M.; Buckner, F.S.; Campbell, R.K.; Carmona, S.; Carruthers, I.M.; Chan, A.W.E.; Chen, F.; Crowther, G.J.; Doyle, M.A.; Hertz-Fowler, C.; Hopkins, A.L.; McAllister, G.; Nwaka, S.; Overington, J.P.; Pain, A.; Paolini, G.V.; Pieper, U.; Ralph, S.A.; Riechers, A.; Roos, D.S.; Sali, A.; Shanmugam, D.; Suzuki, T.; van Voorhis, W.C.; Verlinde, C.L.M.J. Genomic-scale prioritization of drug targets: the TDR Targets database. Nat. Rev. Drug Discov., 2008, 7(11), 900-907.
73. Gao, Z.; Li, H.; Zhang, H.; Liu, X.; Kang, L.; Luo, X.; Zhu, W.; Chen, K.; Wang, X.; Jiang, H. PDTD: a web-accessible protein database for drug target identification. BMC Bioinformatics, 2008, 9(1), 104.
74. Chen, X.; Ji, Z.L.; Chen, Y.Z. TTD: Therapeutic Target Database. Nucleic Acids Res., 2002, 30(1), 412-415.
75. Rose, P.W.; Bi, C.; Bluhm, W.F.; Christie, C.H.; Dimitropoulos, D.; Dutta, S.; Green, R.K.; Goodsell, D.S.; Prlić, A.; Quesada, M.; Quinn, G.B.; Ramos, A.G.; Westbrook, J.D.; Young, J.; Zardecki, C.; Berman P.E.; Bourne, H.M. The RCSB Protein Data Bank: new resources for research and education. Nucleic Acids Res., 2013, 41(D1), D475-D482.
76. Vieth, M.; Siegel, M.G.; Higgs, R.E.; Watson, I.A.; Robertson, D.H.; Savin, K.A.; Durst, G.L.; Hipskind, P.A. Characteristic physical properties and structural fragments of marketed oral drugs. J. Med. Chem., 2003, 47(1), 224-232.
77. Ganesan, A. The impact of natural products upon modern drug discovery. Curr. Opin. Chem. Biol., 2008, 12(3), 306-317.
78. Koch, M.A.; Schuffenhauer, A.; Scheck, M.; Wetzel, S.; Casaulta, M.; Odermatt, A.; Ertl, P.; Waldmann, H. Charting biologically relevant chemical space: A structural classification of natural products (SCONP). Proc. Natl. Acad. Sci. U.S.A., 2005, 102(48), 17272-17277.
79. Reayi, A.; Arya, P. Natural product-like chemical space: search for chemical dissectors of macromolecular interactions. Curr. Opin. Chem. Biol., 2005, 9(3), 240-247.
80. Rosén, J.; Gottfries, J.; Muresan, S.; Backlund, A.; Oprea, T.I. Novel chemical space exploration via natural products. J. Med. Chem., 2009, 52(7), 1953-1962.
81. Osada, H.; Hertweck, C. Exploring the chemical space of microbial natural products. Curr. Opin. Chem. Biol., 2009, 13(2), 133-134.
82. Lachance, H.; Wetzel, S.; Kumar, K.; Waldmann, H. Charting, navigating, and populating natural product chemical space for drug discovery. J. Med. Chem., 2012, 55(13), 5989-6001.
83. Zhou, X.; Li, Y.; Chen, X. Computational identification of bioac-tive natural products by structure activity relationship. J. Mol. Graph. Model., 2010, 29(1), 38-45.
84. Wetzel, S.; Bon, R.S.; Kumar, K.; Waldmann, H. Biology-Oriented Synthesis. Angew. Chem. Int. Ed. Engl., 2011, 50(46), 10800-10826.
85. Newman, D.J.; Cragg, G.M. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod., 2007, 70(3), 461-477.
86. van Hattum, H.; Waldmann, H. Biology-oriented synthesis: harnessing the power of evolution. J. Am. Chem. Soc., 2014, 136(34), 11853-11859.
87. Newman, D.J.; Cragg, G.M. Natural products as sources of new drugs over the 30 years from 1981 to 2010. J. Nat. Prod., 2012, 75(3), 311-335.
88. Hanada, M.; Sugawara, K.; Kaneta, K.; Toda, S.; Nishiyama, Y.; Tomita, K.; Yamamoto, H.; Konishi, M.; Oki, T. Epoxomicin, a new antitumor agent of microbial origin. J. Antibiot. (Tokyo), 1992, 45(11), 1746-1752.
89. Kim, K.B.; Myung, J.; Sin, N.; Crews, C.M. Proteasome inhibition by the natural products epoxomicin and dihydroeponemycin: Insights into specificity and potency. Bioorg. Med. Chem. Lett., 1999, 9(23), 3335-3340.
90. Sin, N.; Kim, K.B.; Elofsson, M.; Meng, L.; Auth, H.; Kwok, B.H.B.; Crews, C.M. Total synthesis of the-potent proteasome inhibitor epoxomicin: a useful tool for understanding proteasome biology. Bioorg. Med. Chem. Lett., 1999, 9(15), 2283-2288.
91. Newman, D.; Giddings, L.A. Natural products as leads to antitumor drugs. Phytochem. Rev., 2014, 13(1), 123-137.
92. Group, C.R.C. Cephalotaxine esters in the treatment of acute leukemia. A preliminary clinical assessment. Chin. Med. J., 1976, 2, 263-272.
93. Fox, E.J. Mechanism of action of mitoxantrone. Neurology, 2004, 63(12 Suppl 6), S15-8.
94. Hande, K.R. Etoposide: four decades of development of a topoiso-merase II inhibitor. Eur. J. Cancer, 1998, 34(10), 1514-1521.
95. Wender, P.A.; Verma, V.A.; Paxton, T.J.; Pillow, T.H. Function-oriented synthesis, step economy, and drug design. Acc. Chem. Res., 2007, 41(1), 40-49.
96. Rizzo, S.; Waldmann, H. Development of a Natural-Product-Derived Chemical Toolbox for Modulation of Protein Function. Chem. Rev., 2014, 114(9), 4621-4639.
97. Wach, J.Y.; Gademann, K. Reduce to the maximum: truncated natural products as powerful modulators of biological processes. Synlett, 2012, 2012(02), 163-170.
98. Surakanti, R.; Sanivarapu, S.; Thulluri, C.; Iyer, P.S.; Tangirala, R.S.; Gundla, R.; Addepally, U.; Murthy, Y.L.N.; Velide, L.; Sen, S. Synthesis of privileged scaffolds by using diversity-oriented synthesis. Chem. Asian J., 2013, 8(6), 1168-1176.
99. Lewis, J.; Bentley, K.; Cowan, A. Narcotic analgesics and antagonists. Annu. Rev. Pharmacol., 1971, 11(1), 241-270.
100. Jain, K.S.; Kathiravan, M.K.; Somani, R.S.; Shishoo, C.J. The biology and chemistry of hyperlipidemia. Bioorg. Med. Chem., 2007, 15(14), 4674-4699.
101. Burke, M.D.; Schreiber, S.L. A planning strategy for diversity-oriented synthesis. Angew. Chem. Int. Ed. Engl., 2004, 43(1), 46-58.
102. Barjau, J.; Schnakenburg, G.; Waldvogel, S.R. Diversity-oriented synthesis of polycyclic scaffolds by modification of an anodic product derived from 2,4-dimethylphenol. Angew. Chem. Int. Ed. Engl., 2011, 50(6), 1415-1419.
103. Sen, S.; Prabhu, G.; Bathula, C.; Hati, S. Diversity-oriented asymmetric synthesis. Synthesis, 2014, 46(16), 2099-2121.
104. Welsch, M.E.; Snyder, S.A.; Stockwell, B.R. Privileged scaffolds for library design and drug discovery. Curr. Opin. Chem. Biol., 2010, 14(3), 347-361.
105. Mackay, H.J.; Twelves, C.J. Protein kinase C: a target for anti-cancer drugs? Endocr. Relat. Cancer, 2003, 10(3), 389-96.
106. Manning, G.; Whyte, D.B.; Martinez, R.; Hunter, T.; Sudarsanam, S. The protein kinase complement of the human genome. Science, 2002, 298(5600), 1912-1934.
107. Walensky, L.D.; Kung, A.L.; Escher, I.; Malia, T.J.; Barbuto, S.; Wright, R.D.; Wagner, G.; Verdine, G.L.; Korsmeyer, S.J. Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science, 2004, 305(5689), 1466-1470.
108. Marquez, V.E.; Blumberg, P.M. Synthetic diacylglycerols (DAG) and DAG-Lactones as activators of protein kinase C (PK-C). Acc. Chem. Res., 2003, 36(6), 434-443.
109. Bon, R.S.; Waldmann, H. Bioactivity-guided navigation of chemical space. Acc. Chem. Res., 2010, 43(8), 1103-1114.
110. Doi, T.; Hoshina, Y.; Mogi, H.; Yamada, Y.; Takahashi, T. Solid-phase combinatorial synthesis of aeruginosin derivatives and their biological evaluation. J. Comb. Chem., 2006, 8(4), 571-582.
111. Nandy, J.P.; Prakesch, M.; Khadem, S.; Reddy, P.T.; Sharma, U.; Arya, P. Advances in solution- and solid-phase synthesis toward the generation of natural product-like libraries. Chem. Rev., 2009, 109(5), 1999-2060.
112. Marfil, M.; Albericio, F.; Álvarez, M. Solid-phase synthesis of lamellarins Q and O. Tetrahedron, 2004, 60(39), 8659-8668.
113. Rivera, D.G.; Vercillo, O.E.; Wessjohann, L.A. Rapid generation of macrocycles with natural-product-like side chains by multiple multicomponent macrocyclizations (MiBs). Org. Biomol. Chem., 2008, 6(10), 1787-1795.
114. Tanaka, N.; Okasaka, M.; Ishimaru, Y.; Takaishi, Y.; Sato, M.; Okamoto, M.; Oshikawa, T.; Ahmed, S.U.; Consentino, L.M.; Lee, K.H. Biyouyanagin A, an anti-HIV agent from Hypericum chinense L. var. salicifolium. Org. Lett., 2005, 7(14), 2997-2999.
115. Wong, F.T.; Khosla, C. Combinatorial biosynthesis of polyketides-a perspective. Curr. Opin. Chem. Biol., 2012, 16(1–2), 117-123.
116. Yoon, Y.J.; Beck, B.J.; Kim, B.S.; Kang, H.Y.; Reynolds, K.A.; Sherman, D.H. Generation of multiple bioactive macrolides by hybrid modular polyketide synthases in Streptomyces venezuelae. Chem. Biol., 9(2), 203-214.
117. Sandmann, G. Combinatorial biosynthesis of carotenoids in a het-erologous host: a powerful approach for the biosynthesis of novel structures. ChemBioChem, 2002, 3(7), 629-635.
118. Cobb, R.; Ning, J.; Zhao, H. DNA assembly techniques for next-generation combinatorial biosynthesis of natural products. J. Ind. Microbiol. Biotechnol., 2014, 41(2), 469-477.
119. Zhang, Y.; Luo, T.; Yang, Z. Strategic innovation in the total synthesis of complex natural products using gold catalysis. Nat. Prod. Rep., 2014, 31(4), 489-503.
120. Corrêa, I.R.; Nören-Müller, A.; Ambrosi, H.D.; Jakupovic, S.; Saxena, K.; Schwalbe, H.; Kaiser, M.; Waldmann, H. Identification of inhibitors for Mycobacterial Protein Tyrosine Phosphatase B (MptpB) by biology-oriented synthesis (BIOS). Chem. Asian J., 2007, 2(9), 1109-1126.
121. Nören-Müller, A.; Reis-Corrêa, I.; Prinz, H.; Rosenbaum, C.; Saxena, K.; Schwalbe, H.J.; Vestweber, D.; Cagna, G.; Schunk, S.; Schwarz, O.; Schiewe, H.; Waldmann, H. Discovery of protein phosphatase inhibitor classes by biology-oriented synthesis. Proc. Natl. Acad. Sci. U. S. A., 2006, 103(28), 10606-10611.
122. Hansch, C.; Fujita, T. p-σ-π Analysis. A method for the correlation of biological activity and chemical structure. J. Am. Chem. Soc. 1964, 86(8), 1616-1626.
123. Hansch, C. Quantitative approach to biochemical structure-activity relationships. Acc. Chem. Res., 1969, 2(8), 232-239.
124. van Westen, G.J.; Wegner, J.K.; IJzerman, A.P.; van Vlijmen, H.W.; Bender, A. Proteochemometric modeling as a tool to design selective compounds and for extrapolating to novel targets. Med-ChemComm, 2011, 2(1), 16-30.
125. Nantasenamat, C.; Isarankura-Na-Ayudhya, C.; Prachayasittikul, V. Advances in computational methods to predict the biological activity of compounds. Expert Opin. Drug Discov., 2010, 5(7), 633-654.
126. Geldenhuys, W.J.; Gaasch, K.E.; Watson, M.; Allen, D.D.; van der Schyf, C.J. Optimizing the use of open-source software applications in drug discovery. Drug Discov. Today, 2006, 11(3–4), 127-132.
127. Nantasenamat, C.; Li, H.; Mandi, P.; Worachartcheewan, A.; Mon-nor, T.; Isarankura-Na-Ayudhya, C.; Prachayasittikul, V. Exploring the chemical space of aromatase inhibitors. Mol. Divers., 2013, 17(4), 661-677.
128. Nabu, S.; Nantasenamat, C.; Owasirikul, W.; Lawung, R.; Isarankura-Na-Ayudhya, C.; Lapins, M.; Wikberg, J.E.S.; Pracha-yasittikul, V. Proteochemometric model for predicting the inhibition of penicillin-binding proteins. J.Comput. Aided Mol. Des., 2014.
129. Nantasenamat, C.; Monnor, T.; Worachartcheewan, A.; Mandi, P.; Isarankura-Na-Ayudhya, C.; Prachayasittikul, V. Predictive QSAR modeling of aldose reductase inhibitors using Monte Carlo feature selection. Eur. J. Med. Chem., 2014, 76, 352-359.
130. Nantasenamat, C.; Worachartcheewan, A.; Mandi, P.; Monnor, T.; Isarankura-Na-Ayudhya, C.; Prachayasittikul, V. QSAR modeling of aromatase inhibition by flavonoids using machine learning approaches. Chem. Papers, 2014, 68(5), 697-713.
131. Pingaew, R.; Mandi, P.; Nantasenamat, C.; Prachayasittikul, S.; Ruchirawat, S.; Prachayasittikul, V. Design, synthesis and molecular docking studies of novel N-benzenesulfonyl-1,2,3,4-tetrahydroisoquinoline-based triazoles with potential anticancer activity. Eur. J. Med.Chem., 2014, 81, 192-203.
132. Pingaew, R.; Saekee, A.; Mandi, P.; Nantasenamat, C.; Prachaya-sittikul, S.; Ruchirawat, S.; Prachayasittikul, V. Synthesis, biological evaluation and molecular docking of novel chalcone-coumarin hybrids as anticancer and antimalarial agents. Eur. J. Med. Chem., 2014, 85, 65-76.
133. Prachayasittikul, V.; Pingaew, R.; Worachartcheewan, A.; Nantasenamat, C.; Prachayasittikul, S.; Ruchirawat, S.; Prachaya-sittikul, V. Synthesis, anticancer activity and QSAR study of 1,4-naphthoquinone derivatives. Eur. J. Med. Chem., 2014, 84, 247-263.
134. Worachartcheewan, A.; Nantasenamat, C.; Isarankura-Na-Ayudhya, C.; Prachayasittikul, V. QSAR study of H1N1 neuram-inidase inhibitors from influenza a virus. Lett. Drug Design Dis-cov., 2014, 11(4), 420-427.
135. Worachartcheewan, A.; Nantasenamat, C.; Owasirikul, W.; Mon-nor, T.; Naruepantawart, O.; Janyapaisarn, S.; Prachayasittikul, S.; Prachayasittikul, V. Insights into antioxidant activity of 1-adamantylthiopyridine analogs using multiple linear regression. Eur. J. Med. Chem., 2014, 73, 258-264.
136. Dudek, A.Z.; Arodz, T.; Galvez, J. Computational methods in developing quantitative structure-activity relationships (QSAR): a review. Comb. Chem. High Throughput Screen., 2006, 9(3), 213-28.
137. Labute, P. A widely applicable set of descriptors. J. Mol. Graph. Model., 2000, 18(4–5), 464-477.
138. Nikolova, N.; Jaworska, J. Approaches to measure chemical similarity – a review. QSAR Comb. Sci., 2003, 22(9-10), 1006-1026.
139. Consonni, V.; Todeschini, R.; Pavan, M. Structure/response correlations and similarity/diversity analysis by GETAWAY descriptors. 1. Theory of the novel 3D molecular descriptors. J. Chem. Inf. Comput. Sci., 2002, 42(3), 682-692.
140. Xue, L.; Bajorath, J. Molecular descriptors in chemoinformatics, computational combinatorial chemistry, and virtual screening. Comb. Chem. High Throughput Screen., 2000, 3(5), 363-372.
141. Tetko, I.; Gasteiger, J.; Todeschini, R.; Mauri, A.; Livingstone, D.; Ertl, P.; Palyulin, V.; Radchenko, E.; Zefirov, N.; Makarenko, A.; Tanchuk, V.; Prokopenko, V. Virtual computational chemistry la- boratory – design and description. J. Comput. Aided Mol. Des., 2005, 19(6), 453-463.
142. Hinselmann, G.; Rosenbaum, L.; Jahn, A.; Fechner, N.; Zell, A. jCompoundMapper: An open source Java library and command-line tool for chemical fingerprints. J. Cheminform., 2011, 3(1), 3.
143. Saeys, Y.; Inza, I.; Larrañaga, P. A review of feature selection techniques in bioinformatics. Bioinformatics, 2007, 23(19), 2507-2517.
144. Zhang, C.; Zhang, S. Association rule mining: models and algorithms; Springer-Verlag, 2002.
145. Pudil, P.; Novovičová, J.; Kittler, J. Floating search methods in feature selection. Pattern Recognit. Lett., 1994, 15(11), 1119-1125.
146. Davis, L. Handbook of genetic algorithms. Vol. 115; Van Nostrand Reinhold: New York, 1991.
147. Quinlan, J.R. C4. 5: programs for machine learning. Vol. 1; Morgan kaufmann: CA, 1993.
148. Landwehr, N.; Hall, M.; Frank, E. Logistic model trees, In: Machine Learning: ECML 2003; Springer, 2003; pp. 241-252.
149. Breiman, L. Random forests. Mach. Learn., 2001, 45(1), 5-32.
150. Jolliffe, I. Principal component analysis; Wiley Online Library, 2005.
151. Geladi, P.; Kowalski, B.R. Partial least-squares regression: a tutorial. Anal. Chim. Acta., 1986, 185, 1-17.
152. Tenenhaus, M. La régression PLS: théorie et pratique; Editions Technip, 1998.
153. Helland, I.S. Some theoretical aspects of partial least squares regression. Chemometr. Intell. Lab. Syst., 2001, 58(2), 97-107.
154. Rosenblatt, F. The perceptron: a probabilistic model for information storage and organization in the brain. Psychol. Rev., 1958, 65(6), 386.
155. Anderson, J.R.; Michalski, R.S.; Carbonell, J.G.; Mitchell, T.M. Machine learning: An artificial intelligence approach. Vol. 2; Morgan Kaufmann, 1986.
156. Russell, S.; Norvig, P. Artificial Intelligence: A Modern Approach, 1st ed.; Prentice-Hall: Egnlewood Cliffs, 1995, 25.
157. Cortes, C.; Vapnik, V. Support-vector networks. Mach. Learn., 1995, 20(3), 273-297.
158. Platt, J. Sequential minimal optimization: A fast algorithm for training support vector machines, 1998.
159. Quinlan, J.R. Simplifying decision trees. Int. J. Man Mach. Stud., 1987, 27(3), 221-234.
160. Hall, M.; Frank, E.; Holmes, G.; Pfahringer, B.; Reutemann, P.; Witten, I.H. The WEKA data mining software: an update. SIGKDD Explor. Newsl., 2009, 11(1), 10-18.
161. Shoombuatong, W.; Hongjaisee, S.; Barin, F.; Chaijaruwanich, J.; Samleerat, T. HIV-1 CRF01_AE coreceptor usage prediction using kernel methods based logistic model trees. Comput. Biol. Med., 2012.
162. Breiman, L.; Friedman, J.; Stone, C.J.; Olshen, R.A. Classification and regression trees; CRC press, 1984.
163. Calle, M.L.; Urrea, V. Letter to the editor: Stability of random forest importance measures. Brief. Bioinform., 2011, 12(1), 86-89.
164. Breiman, L.; Friedman, J.H.; Olshen, R.A.; Stone, C.J. Classification and regression trees; Wadsworth & Brooks: Monterey, CA, 1984.
165. Bishop, C.M., Pattern recognition and machine learning. Vol. 1; Springer: New York, 2006.
166. Golbraikh, A.; Tropsha, A. Beware of q2! J. Mol. Graph. Model., 2002, 20(4), 269-276.
167. Melagraki, G.; Afantitis, A. Enalos KNIME nodes: Exploring corrosion inhibition of steel in acidic medium. Chemometr. Intell. Lab. Syst., 2013, 123(0), 9-14.
168. Zhang, S.; Golbraikh, A.; Oloff, S.; Kohn, H.; Tropsha, A. A novel automated lazy learning QSAR (ALL-QSAR) approach: method development, applications, and virtual screening of chemical databases using validated ALL-QSAR models. J. Chem. Inf. Model., 2006, 46(5), 1984-1995.
169. Refaeilzadeh, P.; Tang, L.; Liu, H. Cross-validation, In: Encyclopedia of database systems; Springer, 2009; pp. 532-538.
170. Xu, J.; Wang, L.; Wang, L.; Shen, X.; Xu, W. QSPR study of Setschenow constants of organic compounds using MLR, ANN, and SVM analyses. J. Comput. Chem., 2011, 32(15), 3241-3252.
171. Melagraki, G.; Afantitis, A. Enalos InSilicoNano platform: an online decision support tool for the design and virtual screening of nanoparticles. RSC Adv., 2014, 4(92), 50713-50725.
172. Hinde, J.; Demétrio, C.G. Overdispersion: models and estimation. Comput. Stat. Data Anal., 1998, 27(2), 151-170.
173. Gaurav, A.; Gautam, V.; Pereira, S.; Alvarez-Leite, J.; Vetri, F.; Choudhury, M.; Pelligrino, D.; Sundivakkam, P.; Radhakrishnan, K.; Krieger, A. Structure-based three-dimensional pharmacophores as an alternative to traditional methodologies. J. Receptor Ligand Channel Res., 2014, 7, 27-38.
174. Guner, O.F. History and evolution of the pharmacophore concept in computer-aided drug design. Curr. Top. Med. Chem., 2002, 2(12), 1321-32.
175. Strebhardt, K.; Ullrich, A. Paul Ehrlich's magic bullet concept: 100 years of progress. Nat. Rev. Cancer, 2008, 8(6), 473-480.
176. Kurogi, Y.; Guner, O.F. Pharmacophore modeling and three-dimensional database searching for drug design using catalyst. Curr. Med. Chem., 2001, 8(9), 1035-55.
177. Langer, T.; Krovat, E.M. Chemical feature-based pharmacophores and virtual library screening for discovery of new leads. Curr. Opin. Drug Discov. Devel., 2003, 6(3), 370-6.
178. Franke, L.; Byvatov, E.; Werz, O.; Steinhilber, D.; Schneider, P.; Schneider, G. Extraction and visualization of potential pharmaco-phore points using support vector machines: application to ligand-based virtual screening for COX-2 inhibitors. J. Med. Chem., 2005, 48(22), 6997-7004.
179. Leach, A.R.; Gillet, V.J.; Lewis, R.A.; Taylor, R. Three-dimensional pharmacophore methods in drug discovery. J. Med. Chem., 2009, 53(2), 539-558.
180. Guner, O.F. Pharmacophore perception, development, and use in drug design; International University Line: La Jolla, CA., 2000.
181. Langer, T.; Hoffmann, R.D. Pharmacophore modelling: applications in drug discovery. Expert Opin. Drug Discov., 2006, 1(3), 261-7.
182. Sanders, M.P.A.; McGuire, R.; Roumen, L.; de Esch, I.J.P.; de Vlieg, J.; Klomp, J.P.G.; de Graaf, C. From the protein's perspective: the benefits and challenges of protein structure-based pharma-cophore modeling. MedChemComm, 2012, 3(1), 28-38.
183. Yang, S.Y. Pharmacophore modeling and applications in drug discovery: challenges and recent advances. Drug Discov. Today, 2010, 15(11–12), 444-450.
184. Cramer, R.D.; Patterson, D.E.; Bunce, J.D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins. J. Am. Chem. Soc., 1988, 110(18), 5959-5967.
185. Chin, W.W. The partial least squares approach to structural equation modeling, In: Modern methods for business research; Marcou-lides, G.A., Ed.; Lawrence Erlbaum Associates Publishers: Mah-wah, NJ, US, 1998; pp. 295-336.
186. Wolber, G.; Seidel, T.; Bendix, F.; Langer, T. Molecule-pharmacophore superpositioning and pattern matching in computational drug design. Drug Discov. Today, 2008, 13(1–2), 23-29.
187. Martin, Y.; Bures, M.; Danaher, E.; DeLazzer, J.; Lico, I.; Pavlik, P. A fast new approach to pharmacophore mapping and its application to dopaminergic and benzodiazepine agonists. J. Comput. Aided Mol. Des., 1993, 7(1), 83-102.
188. Chang, C.; Swaan, P.W.; Ngo, L.Y.; Lum, P.Y.; Patil, S.D.; Unad-kat, J.D. Molecular requirements of the human nucleoside transporters hCNT1, hCNT2, and hENT1. Mol. Pharm., 2004, 65(3), 558-570.
189. Le Bourdonnec, B.; Cauvin, C.; Meulon, E.; Yous, S.; Goossens, J.F.; Durant, F.; Houssin, R.; Hénichart, J.P. Comparison of 3D structures and AT1 binding properties of pyrazolidine-3,5-diones and tetrahydropyridazine-3,6-diones with parent antihypertensive drug irbesartan. J. Med. Chem., 2002, 45(21), 4794-4798.
190. Fossa, P.; Boggia, R.; Lo Presti, E.; Mosti, L.; Dorigo, P.; Floreani, M. Inotropic agents. Synthesis and structure-activity relationships of new milrinone related cAMP PDE III inhibitors. Farmaco, 1997, 52(8-9), 523-30.
191. Nicolotti, O.; Pellegrini-Calace, M.; Carrieri, A.; Altomare, C.; Centeno, N.B.; Sanz, F.; Carotti, A. Neuronal nicotinic receptor agonists: a multi-approach development of the pharmacophore. J. Comput. Aided Mol. Des., 2001, 15(9), 859-872.
192. Schuster, I.; Egger, H.; Nussbaumer, P.; Kroemer, R.T. Inhibitors of vitamin D hydroxylases: Structure–activity relationships. J. Cell Biochem., 2003, 88(2), 372-380.
193. Fossa, P.; Boggia, R.; Mosti, L. Toward the identification of the cardiac cGMP inhibited-phosphodiesterase catalytic site. J. Com-put. Aided Mol. Des., 1998, 12(4), 361-361.
194. Jones, G.; Willett, P.; Glen, R.C. GASP: genetic algorithm super-imposition program, In: Pharmacophore Perception, Development, and Use in Drug Design; International University Line: La Jolla, CA, USA, 2000; pp. 85-106.
195. Barnum, D.; Greene, J.; Smellie, A.; Sprague, P. Identification of common functional configurations among molecules. J. Chem. Inf. Comput. Sci., 1996, 36(3), 563-571.
196. Li, H.; Sutter, J.; Hoffmann, R. HypoGen: an automated system for generating 3D predictive pharmacophore models, In: Pharmaco-phore Perception, Development, and Use in Drug Design; International University Line: La Jolla, CA, USA, 2000; pp. 171.
197. Chemical Computing Group. Molecular Operating Environment (MOE) v2006.08; Chemical Computing Group: Montreal, Quebec, Canada, 2006.
198. Dixon, S.; Smondyrev, A.; Knoll, E.; Rao, S.; Shaw, D.; Friesner, R. PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J. Comput. Aided Mol. Des., 2006, 20(10-11), 647-671.
199. Richmond, N.J.; Abrams, C.A.; Wolohan, P.R.; Abrahamian, E.; Willett, P.; Clark, R.D. GALAHAD: 1. Pharmacophore identification by hypermolecular alignment of ligands in 3D. J. Comput. Aided Mol. Des., 2006, 20(9), 567-587.
200. Wolber, G.; Langer, T. LigandScout: 3D Pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J. Chem. Inf. Model., 2004, 45(1), 160-169.
201. Alonso, H.; Bliznyuk, A.A.; Gready, J.E. Combining docking and molecular dynamic simulations in drug design. Med. Res. Rev., 2006, 26(5), 531-568.
202. Halperin, I.; Ma, B.; Wolfson, H.; Nussinov, R. Principles of docking: an overview of search algorithms and a guide to scoring functions. Proteins Struct. Funct. Genet., 2002, 47(4), 409-443.
203. Brooijmans, N.; Kuntz, I.D. Molecular recognition and docking algorithms. Annu. Rev. Biophys. Biomol. Struct., 2003, 32(1), 335-373.
204. Kitchen, D.B.; Decornez, H.; Furr, J.R.; Bajorath, J. Docking and scoring in virtual screening for drug discovery: methods and applications. Nat. Rev. Drug Discov., 2004, 3(11), 935-949.
205. Li, J. Basic molecular dynamics, In: Handbook of Materials Modeling; Springer, 2005, pp. 565-588.
206. Adcock, S.A.; McCammon, J.A. Molecular dynamics: survey of methods for simulating the activity of proteins. Chem. Rev., 2006, 106(5), 1589-1615.
207. Galeazzi, R. Molecular dynamics as a tool in rational drug design: current status and some major applications. Curr. Comput. Aided Drug Des., 2009, 5(4), 225-240.
208. Kortagere, S.; Lill, M.; Kerrigan, J. Role of computational methods in pharmaceutical sciences, In: Computational Toxicology; Springer, 2012; pp. 21-48.
209. Ian, I.F.; Luis, R.T.J.; Pablo, C.V.J.; Luis, V.S.J.; Normande, C.I.; Beatriz, Z.L.; Sandino, R.L.C.A.; Guadalupe, B.C.C.; Jose, C.B.; Absalom, Z.C. Identification of pharmacological targets combining docking and molecular dynamics simulations. Am. J. Agric. Biol. Sci., 2013, 8(1), 89.
210. Ma, D.L.; Chan, D.S.H.; Leung, C.H. Molecular docking for virtual screening of natural product databases. Chem. Sci., 2011, 2(9), 1656-1665.
211. Medina-Franco, J.L.; López-Vallejo, F.; Kuck, D.; Lyko, F. Natural products as DNA methyltransferase inhibitors: a computer-aided discovery approach. Mol. Divers., 2011, 15(2), 293-304.
212. Du, H.; Wang, J.; Watzl, J.; Zhang, X.; Hu, Z. Classification structure–activity relationship (CSAR) studies for prediction of geno-toxicity of thiophene derivatives. Toxicol. Lett., 2008, 177(1), 10-19.
213. Ma, S.K.; Wu, K.Z.; Li, A.X. Virtual screening for natural product inhibitors of HIV-1 integrase. Interdiscip. Sci., 2011, 3(1), 17-21.
214. Lemkul, J.A.; Bevan, D.R. Morin inhibits the early stages of amyloid beta-peptide aggregation by altering tertiary and quaternary in-teractions to produce "off-pathway" structures. Biochemistry, 2012, 51(30), 5990-6009.
215. Hou, D.X.; Kumamoto, T. Flavonoids as protein kinase inhibitors for cancer chemoprevention: direct binding and molecular modeling. Antioxid. Redox. Signal., 2010, 13(5), 691-719.
216. Chen, C.Y.C. TCM Database@ Taiwan: the world's largest traditional Chinese medicine database for drug screening in silico. PLoS One, 2011, 6(1), e15939.
217. Sun, M.F.; Yang, S.C.; Chang, K.W.; Tsai, T.Y.; Chen, H.Y.; Tsai, F.J.; Lin, J.G.; Chen, C.Y.C. Screening from TCM Database@ Taiwan and QSAR model for identifying HER2 inhibitors. Mol. Simul., 2011, 37(10), 884-892.
218. Yang, S.C.; Chang, S.S.; Chen, H.Y.; Chen, C.Y.C. Identification of potent EGFR inhibitors from TCM Database@Taiwan. PLoS Comput. Biol., 2011, 7(10), e1002189.
219. Yang, S.C.; Chang, S.S.; Chen, C.Y.C. Identifying HER2 inhibitors from natural products database. PLoS One, 2011, 6(12), e28793.
220. Khuntawee, W.; Rungrotmongkol, T.; Hannongbua, S. Molecular dynamic behavior and binding affinity of flavonoid analogues to the cyclin dependent kinase 6/cyclin D complex. J. Chem. Inf. Model., 2011, 52(1), 76-83.
221. Yim-Im, W.; Sawatdichaikul, O.; Semsri, S.; Horata, N.; Mokmak, W.; Tongsima, S.; Suksamrarn, A.; Choowongkomon, K. Computational analyses of curcuminoid analogs against kinase domain of HER2. BMC Bioinformatics, 2014, 15(1), 1-13.
222. Ngo, S.T.; Li, M.S. Curcumin binds to Abeta1-40 peptides and fibrils stronger than ibuprofen and naproxen. J. Phys. Chem. B., 2012, 116(34), 10165-75.
223. Ngo, S.T.; Li, M.S. Top-leads from natural products for treatment of Alzheimer's disease: docking and molecular dynamics study. Mol. Simul., 2013, 39(4), 279-291.
224. Lemkul, J.A.; Bevan, D.R. Destabilizing Alzheimer's Abeta(42) protofibrils with morin: mechanistic insights from molecular dynamics simulations. Biochemistry, 2010, 49(18), 3935-46.
225. Lemkul, J.A.; Bevan, D.R. The role of molecular simulations in the development of inhibitors of amyloid beta-peptide aggregation for the treatment of Alzheimer's disease. ACS Chem. Neurosci., 2012, 3(11), 845-56.
226. Liu, M.Y.; Chen, K.J. Convergence: The tradition and the modern. Chin. J. Integr. Med., 2012, 18(3), 164-165.
227. Eisenberg, D. Reflections on the past and future of integrative medicine from a lifelong student of the integration of Chinese and Western Medicine. Chin. J. Integr. Med., 2011, 17(1), 3-5.
228. Chaudhary, A.; Singh, N. Contribution of world health organization in the global acceptance of Ayurveda. J. Ayurveda Integr. Med., 2011, 2(4), 179.
229. Xu, H.; Chen, K.J. Complementary and alternative medicine: is it possible to be mainstream? Chin. J. Integr. Med., 2012, 18(6), 403-404.
230. Weil, A. The state of the integrative medicine in the US and Western World. Chin. J. Integr. Med., 2011, 17(1), 6-10.
231. Park, J.; Beckman-Harned, S.; Cho, G.; Kim, D.; Kim, H. The current acceptance, accessibility and recognition of Chinese and Ayurvedic medicine in the United States in the public, governmental, and industrial sectors. Chin. J. Integr. Med., 2012, 18(6), 405-408.
232. Manek, N.; Crowson, C.; Ottenberg, A.; Curlin, F.; Kaptchuk, T.; Tilburt, J. What rheumatologists in the United States think of complementary and alternative medicine: results of a national survey. BMC Complement. Altern. Med., 2010, 10(1), 5.
233. Lu, W.I.; Lu, D.P. Impact of Chinese herbal medicine on American society and health care system: perspective and concern. Evid. Based Complement. Alternat. Med., 2014, 2014, 6.
234. David, B.; Wolfender, J.L.; Dias, D. The pharmaceutical industry and natural products: historical status and new trends. Phytochem. Rev., 2014, 1-17.
235. Sahoo, N.; Manchikanti, P.; Dey, S. Herbal drugs: Standards and regulation. Fitoterapia, 2010, 81(6), 462-471.